Showing Results for
- Academic Journals (17)
Search Results
- 17
Academic Journals
- 17
- 1From:Oncology (Vol. 35, Issue 6) Peer-ReviewedThe authors of the accompanying article review the rapidly evolving treatment paradigms for renal cell carcinoma in both the first- and second-line settings. A remarkable sea change has occurred over the past 3-plus...
- 2From:Oncology (Vol. 35, Issue 6) Peer-ReviewedTreatment selection for patients with hematologic malignancies involves a vast knowledge of variations in biology and the rapidly evolving field of systemic therapy development. With options for transplant, chimeric...
- 3From:Oncology (Vol. 35, Issue 6) Peer-ReviewedQ: Can you briefly describe the mechanism of action of tazemetostat? Tazemetostat is a novel, first-in-class EZH2 inhibitor that is approved for follicular lymphoma. EZH2 is a histone methyltransferase that is abundant...
- 4From:Oncology (Vol. 35, Issue 6) Peer-ReviewedTITLE : NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR/MSI-H Immunotherapy (COMMIT) Study: A Randomized Phase 3 Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination vs Single Agent Atezolizumab in the...
- 5From:Oncology (Vol. 35, Issue 6) Peer-ReviewedAround the Practice is a monthly urologic virtual live event featuring case reviews from multidisciplinary experts, presented by Urology Times[R] in partnership with the Large Urology Group Practice Association. On April...
- 6From:Oncology (Vol. 35, Issue 6) Peer-ReviewedFollicular lymphoma (FL) is an indolent B-cell lymphoproliferative disease that accounts for approximately 20% of all cases of non-Hodgkin lymphoma. (1) CancerNetwork[R] met with Sameh Gaballa, MD, of Mofitt Cancer...
- 7From:Oncology (Vol. 35, Issue 6) Peer-ReviewedNeed a mortgage approved to buy a $400,000 house in less than an hour or specialty pet food delivered to your door by tomorrow? No problem. Need your patient to switch from warfarin (Coumadin) to enoxaparin (Lovenox)...
- 8From:Oncology (Vol. 35, Issue 6) Peer-ReviewedThanks to rapid innovation and unmatched dedication from investigators and oncology care providers, patients with cancer are living longer than ever before, motivating further research into optimizing patient outcomes...
- 9From:Oncology (Vol. 35, Issue 6) Peer-ReviewedTHE CASE A nulliparous woman, age 25 years, had received a diagnosis of non-Hodgkin lymphoma (NHL) and now presented with stage IIA diffuse large B-cell lymphom a (DLBCL). According to her hematological oncologist's...
- 10From:Oncology (Vol. 35, Issue 6) Peer-ReviewedApproximately 270,000 women are diagnosed with breast cancer each year in the United States alone. While there is consensus among national organizations including the US Preventive Services Task Force, the American...
- 11From:Oncology (Vol. 35, Issue 6) Peer-ReviewedHistorically, patients with stage IV non-small cell lung cancer (NSCLC) have been treated with chemotherapy alone, reserving local therapies for symptom palliation. However, evidence has accumulated that a subset of...
- 12From:Oncology (Vol. 35, Issue 6) Peer-ReviewedLEARNING OBJECTIVES Upon successful completion of this activity, you should be better prepared to: * Describe the physiologic function of TAp63 in breast cancer * Explain the rationale for targeting TAp63 as a...
- 13From:Oncology (Vol. 35, Issue 6) Peer-ReviewedRecent developments in HER2-targeted therapy present new challenges for physicians treating patients with metastatic HER2-positive (HER2+) breast cancer, including how to treat patients with brain metastases, how to...
- 14From:Oncology (Vol. 35, Issue 6) Peer-ReviewedIn the setting of hormone receptor--positive (HR+), HER2-negative, lymph node-negative (pN0) breast cancer, postsurgical antiestrogen therapy (ie, adjuvant endocrine therapy) with tamoxifen or an aromatase inhibitor is...
- 15From:Oncology (Vol. 35, Issue 6) Peer-ReviewedIn recent years, first-line therapies for metastatic renal cell carcinoma (mRCC) have shifted to a combination of immune checkpoint inhibitors or a combination of antiangiogenesis tyrosine kinase inhibitors (TKIs) and...
- 16From:Oncology (Vol. 35, Issue 6) Peer-ReviewedA landmark study published in 2007 by the American Society of Clinical Oncology (ASCO) predicted a major shortfall of medical oncologists by the year 2020. (1) This study, which was done in conjunction with the...
- 17From:Oncology (Vol. 35, Issue 6) Peer-ReviewedAppendiceal mucinous neoplasms are a rare and heterogeneous group of diseases with challenging clinical management decisions. They account for less than 1% of all cancers but their incidence is on the rise. Treatment is...